Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $19.50.

A number of analysts recently issued reports on CTNM shares. Morgan Stanley reiterated an “equal weight” rating and issued a $14.00 price target (down from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Wall Street Zen lowered Contineum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Robert W. Baird upped their target price on Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st.

Contineum Therapeutics Price Performance

CTNM stock opened at $13.25 on Thursday. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.33. The firm’s 50-day moving average is $13.96 and its 200 day moving average is $12.43. The company has a market capitalization of $494.76 million, a PE ratio of -6.08 and a beta of 1.38.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.01. Sell-side analysts forecast that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTNM. Strs Ohio purchased a new position in Contineum Therapeutics during the 1st quarter valued at about $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Contineum Therapeutics in the 4th quarter worth approximately $43,000. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics in the 2nd quarter worth approximately $43,000. Marex Group plc bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $45,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $76,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.